Indicated for the treatment of infections caused by bacteria sensitive to Clindamycin, such as Staphylococcus, Streptococcus, and anaerobic bacteria such as Bacteroides spp., Fusobacterium spp., Peptoestreptococcus spp., Clostridium perfringens and many species of Propionibacterium spp. It also shows activity against Toxoplasma gondii. Its use is indicated for the treatment of infections caused by bacteria sensitive to Clindamycin in dogs and cats. In dogs, its use is recommended as the therapy of choice for the treatment of oral infections, pyoderma and osteomyelitis. In cats, its use is especially recommended for the treatment of oral infections. Clindamycin is also indicated in cases of toxoplasmosis in dogs and cats, as it improves the clinical signs associated with active infection with Toxoplasma gondii.

Clindamycin is an antibiotic belonging to the Lincosamide group, which is a semi-synthetic modification of Lincomycin. It has an action spectrum similar to Erythromycin, i.e., gram-positive bacteria, especially staphylococci, streptococci and anaerobic bacteria. Lincosamides are useful for the treatment of infections resistant to Penicillin, Erythromycin and Cephalosporins. Clindamycin inhibits bacterial protein synthesis, altering translocation. It binds to the 50S subunit of the bacterial ribosome, preventing the translocation of transfer RNA from the A site to the P site of the ribosome, preventing the formation of peptide bonds and generating the inhibition of protein synthesis of the microorganism. Each 620 mg tablet contains: Clindamycin Hydrochloride..............195.04 mg (Equivalent to 165 mg of Clindamycin base) Excipients q.s.p...........................620 mg
Place of origin

Chile

Sale only with veterinary prescription.